| Functional delivery of viral miRNAs via exosomes DM Pegtel, K Cosmopoulos, DA Thorley-Lawson, MAJ van Eijndhoven, ... Proceedings of the National Academy of Sciences 107 (14), 6328-6333, 2010 | 1918 | 2010 |
| Langerin is a natural barrier to HIV-1 transmission by Langerhans cells L de Witte, A Nabatov, M Pion, D Fluitsma, MAWP De Jong, T de Gruijl, ... Nature medicine 13 (3), 367-371, 2007 | 813 | 2007 |
| Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer AN Niemeijer, D Leung, MC Huisman, I Bahce, OS Hoekstra, ... Nature communications 9 (1), 4664, 2018 | 456 | 2018 |
| Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration … AJM Van den Eertwegh, J Versluis, HP Van den Berg, SJAM Santegoets, ... The lancet oncology 13 (5), 509-517, 2012 | 410 | 2012 |
| High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy B Geboers, HJ Scheffer, PM Graybill, AH Ruarus, S Nieuwenhuizen, ... Radiology 295 (2), 254-272, 2020 | 332 | 2020 |
| Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix AM Heeren, S Punt, MCG Bleeker, KN Gaarenstroom, J Van Der Velden, ... Modern Pathology 29 (7), 753-763, 2016 | 309 | 2016 |
| CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses RA Rosalia, LJ Cruz, S van Duikeren, AT Tromp, AL Silva, W Jiskoot, ... Biomaterials 40, 88-97, 2015 | 305 | 2015 |
| Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation CC Sombroek, AGM Stam, AJ Masterson, SM Lougheed, MJAG Schakel, ... The Journal of Immunology 168 (9), 4333-4343, 2002 | 264 | 2002 |
| Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines TD De Gruijl, AJM Van Den Eertwegh, HM Pinedo, RJ Scheper Cancer Immunology, Immunotherapy 57, 1569-1577, 2008 | 248 | 2008 |
| Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector BW Tillman, TD Gruijl, SA Bakker, RJ Scheper, HM Pinedo, TJ Curiel, ... The Journal of Immunology 162 (11), 6378-6383, 1999 | 237 | 1999 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 226 | 2019 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial DA Palma, R Olson, S Harrow, RJM Correa, F Schneiders, CJA Haasbeek, ... BMC cancer 19, 1-15, 2019 | 225 | 2019 |
| Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry SJAM Santegoets, EM Dijkgraaf, A Battaglia, P Beckhove, CM Britten, ... Cancer Immunology, Immunotherapy 64, 1271-1286, 2015 | 220 | 2015 |
| MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors AJ Masterson, CC Sombroek, TD De Gruijl, YMF Graus, HJJ Van Der Vliet, ... Blood, The Journal of the American Society of Hematology 100 (2), 701-703, 2002 | 218 | 2002 |
| Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT) T Van Den Ende, NC De Clercq, MI van Berge Henegouwen, SS Gisbertz, ... Clinical Cancer Research 27 (12), 3351-3359, 2021 | 206 | 2021 |
| Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients J Haanen, A Baars, R Gomez, P Weder, M Smits, TD De Gruijl, ... Cancer Immunology, Immunotherapy 55, 451-458, 2006 | 200 | 2006 |
| The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments JP Veluchamy, N Kok, HJ van der Vliet, HMW Verheul, TD de Gruijl, ... Frontiers in immunology 8, 631, 2017 | 199 | 2017 |
| Defining the critical hurdles in cancer immunotherapy BA Fox, DJ Schendel, LH Butterfield, S Aamdal, JP Allison, PA Ascierto, ... Journal of translational medicine 9, 1-15, 2011 | 194 | 2011 |
| Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells WWJ Unger, AJ Van Beelen, SC Bruijns, M Joshi, CM Fehres, ... Journal of Controlled Release 160 (1), 88-95, 2012 | 182 | 2012 |
| CD4+CD25hi regulatory T‐cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical … JW Molling, TD De Gruijl, J Glim, M Moreno, L Rozendaal, CJLM Meijer, ... International journal of cancer 121 (8), 1749-1755, 2007 | 179 | 2007 |
Saskia Santegoets確認したメール アドレス: lumc.nl
